RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT: TRXC) (“TransEnterix”), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has expanded the clinical adoption of the Senhance Robotic Surgical System (“the Senhance”) to include a full range of hernia repair surgeries.
Hernia repairs represent one of the largest procedural opportunities for the Senhance. Millennium Research Group has estimated that during 2017, there will be a total of 1,080,400 hernia repair surgeries in Europe1 and 1,156,300 hernia repair surgeries in the United States2.
“Robotic hernia repair with the Senhance system represents a significant procedural area for our technology,” said Todd M. Pope, President and CEO of TransEnterix. “Hernia repairs, both inguinal and ventral, are amongst the most common surgical procedures performed worldwide. These procedures also represent one of the fastest growing uses of robotics in surgery. The introduction of Senhance to provide robotic assistance in these procedures brings a system with haptic feedback and attractive procedural costs to these operations for the first time.”
St. Marien-Krankenhaus Siegen in Germany, a major hernia repair center in Germany that performs over 500 hernia repairs annually, was the first site to begin using the Senhance for unilateral and bilateral inguinal hernia repairs as well as ventral hernia repairs. Dr. Dietmar Stephan and Prof. Dr. Frank Willeke performed up to three robotic hernia surgeries per day with the Senhance during the first weeks of its clinical use at the hospital. This allows the team to adopt Senhance to include the day’s full operating schedule.
“We are pleased to offer robotic hernia repair utilizing the Senhance Robotic System, and all our operations utilizing this advanced technology have been performed with precision, safety and efficiency. The 3D visualization and precise control of the robotic instruments and camera are very helpful during delicate surgical tasks. The haptic feedback of the system is vital, and it allows me to feel the location of critical structures such as the pubic bone which aren’t always visible,” said Dr. Dietmar Stephan, Director of the Center for Minimally Invasive Surgery at St. Marien. “The Senhance is a significant progression in the field of minimally invasive hernia repair, and allows me to fully incorporate robotics into my hernia practice without having to justify high additional procedural costs.”
TransEnterix will be exhibiting the Senhance Surgical System at two major surgical conferences: The Society of American Gastrointestinal and Endoscopic Surgeons in Houston, Texas which will be held March 22-25, 2017, and the Kongress Deutsche Gesellschaft für Chirurgen, the largest general surgery meeting in Germany, in Munich being held March 21-23, 2017. The Senhance will be available for surgeon evaluations at both events, and Dr. Dietmar Stephan will be discussing his technique of robotic hernia repair with Senhance at the German surgical meeting.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the introduction of the Senhance System to provide robotic assistance in hernia procedures brings a system with haptic feedback and attractive procedural costs to these operations for the first time. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 6, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
1 Millennium Research Group, Laparoscopic Devices Europe 2014 Market Analysis
2 Millennium Research Group, Medtech 360: Laparoscopic Devices US 2016 Market Analysis
